Omeros Co. (NASDAQ:OMER) Given Average Rating of “Moderate Buy” by Analysts

Omeros Co. (NASDAQ:OMER) has received a consensus recommendation of “Moderate Buy” from the five analysts that are presently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $22.50.

Several research firms recently weighed in on OMER. StockNews.com upgraded shares of Omeros from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Rodman & Renshaw started coverage on shares of Omeros in a research report on Thursday, November 14th. They set a “buy” rating and a $9.00 price target on the stock. D. Boral Capital started coverage on shares of Omeros in a report on Monday. They issued a “buy” rating and a $36.00 price objective for the company. RODMAN&RENSHAW raised Omeros to a “strong-buy” rating in a research report on Thursday, November 14th. Finally, Cantor Fitzgerald restated a “neutral” rating on shares of Omeros in a research report on Thursday, November 14th.

Hedge Funds Weigh In On Omeros

Several large investors have recently made changes to their positions in the business. Geode Capital Management LLC increased its position in Omeros by 0.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,339,251 shares of the biopharmaceutical company’s stock valued at $5,318,000 after buying an additional 6,839 shares in the last quarter. State Street Corp grew its position in Omeros by 0.3% during the 3rd quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company’s stock valued at $4,867,000 after purchasing an additional 3,839 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Omeros by 4.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 485,035 shares of the biopharmaceutical company’s stock valued at $1,926,000 after buying an additional 18,454 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Omeros by 16.6% during the second quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company’s stock valued at $887,000 after acquiring an additional 31,081 shares in the last quarter. Finally, Rhumbline Advisers increased its position in shares of Omeros by 6.1% during the second quarter. Rhumbline Advisers now owns 111,778 shares of the biopharmaceutical company’s stock valued at $454,000 after acquiring an additional 6,435 shares in the last quarter. 48.79% of the stock is currently owned by hedge funds and other institutional investors.

Omeros Price Performance

OMER opened at $10.31 on Monday. Omeros has a one year low of $2.61 and a one year high of $13.60. The business has a 50 day simple moving average of $7.09 and a two-hundred day simple moving average of $5.20. The firm has a market capitalization of $597.46 million, a price-to-earnings ratio of -4.46 and a beta of 1.97.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.